Rein Therapeutics Inc (RNTX)

$1.20 +0.01 (0.84%)
Market Cap 31.54M
Revenue (ttm) 0.00
Net Income (ttm) -62.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 77,200
Avg Vol 138,420
Day's Range N/A - N/A
Shares Out 26.29M
Stochastic %K 44%
Beta 1.51
Analysts Sell
Price Target $10.00

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 802 1989
Address:
12407 N. Mopac Expy., Suite 250 #390, Austin, United States
BioTuesdays
BioTuesdays Mar. 3 at 5:31 PM
$RNTX has announced that the first patient has been dosed in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. https://biotuesdays.com/2026/03/03/rein-doses-first-patient-in-phase-2-trial-of-lti-03-in-ipf/
0 · Reply
BrianWindsor
BrianWindsor Mar. 3 at 2:11 PM
First patient officially dosed in our Phase 2 trial of LTI-03 for IPF. This follows FDA clearance to resume the program and marks an important step in advancing our lead asset. Randomized, placebo-controlled study. ~120 patients. Interim data expected in 2H 2026. Appreciate everyone following our progress as we execute! $RNTX #IPF https://www.youtube.com/shorts/00BmERCURu4
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 2:10 PM
$RNTX RSI: 52.00, MACD: -0.0242 Vol: 0.11, MA20: 1.22, MA50: 1.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
InstitutionalAllocator
InstitutionalAllocator Feb. 20 at 1:07 PM
$RNTX Rein Therapeutics focuses on rare pulmonary diseases. Clinical milestones drive valuation. Development risk remains high.
0 · Reply
CapitalMarketsView
CapitalMarketsView Feb. 17 at 12:58 PM
$RNTX Pre-revenue biotech; early-stage.
0 · Reply
MomentumWins
MomentumWins Feb. 13 at 5:07 PM
$RNTX What’s happening with this one? holding bags here 1.55
0 · Reply
wolfcyd3
wolfcyd3 Feb. 11 at 4:42 PM
$RNTX added 20k shares today
1 · Reply
BatteryBaron
BatteryBaron Feb. 9 at 2:58 PM
$RNTX Renal therapy biotech; faces established standard of care.
0 · Reply
Dlslfl
Dlslfl Jan. 30 at 10:52 PM
$RNTX bullish? :) u guy's all stupid Me too
0 · Reply
Dlslfl
Dlslfl Jan. 27 at 4:46 AM
$RNTX have news?
0 · Reply
Latest News on RNTX
Why Is Rein Therapeutics Stock Trading Higher On Monday?

Nov 3, 2025, 1:17 PM EST - 4 months ago

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Oct 9, 2025, 7:30 AM EDT - 5 months ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Sep 17, 2025, 7:30 AM EDT - 6 months ago

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Aug 19, 2025, 8:00 AM EDT - 7 months ago

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Aug 14, 2025, 5:00 PM EDT - 7 months ago

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Jun 24, 2025, 10:11 AM EDT - 9 months ago

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Jun 12, 2025, 5:18 PM EDT - 9 months ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025, 4:51 PM EDT - 10 months ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:09 PM EDT - 10 months ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 11 months ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 28, 2025, 7:00 AM EDT - 11 months ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 23, 2025, 7:00 AM EDT - 11 months ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 15, 2025, 7:00 AM EDT - 11 months ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 7, 2025, 4:17 PM EDT - 11 months ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

BioTuesdays
BioTuesdays Mar. 3 at 5:31 PM
$RNTX has announced that the first patient has been dosed in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. https://biotuesdays.com/2026/03/03/rein-doses-first-patient-in-phase-2-trial-of-lti-03-in-ipf/
0 · Reply
BrianWindsor
BrianWindsor Mar. 3 at 2:11 PM
First patient officially dosed in our Phase 2 trial of LTI-03 for IPF. This follows FDA clearance to resume the program and marks an important step in advancing our lead asset. Randomized, placebo-controlled study. ~120 patients. Interim data expected in 2H 2026. Appreciate everyone following our progress as we execute! $RNTX #IPF https://www.youtube.com/shorts/00BmERCURu4
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 2:10 PM
$RNTX RSI: 52.00, MACD: -0.0242 Vol: 0.11, MA20: 1.22, MA50: 1.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
InstitutionalAllocator
InstitutionalAllocator Feb. 20 at 1:07 PM
$RNTX Rein Therapeutics focuses on rare pulmonary diseases. Clinical milestones drive valuation. Development risk remains high.
0 · Reply
CapitalMarketsView
CapitalMarketsView Feb. 17 at 12:58 PM
$RNTX Pre-revenue biotech; early-stage.
0 · Reply
MomentumWins
MomentumWins Feb. 13 at 5:07 PM
$RNTX What’s happening with this one? holding bags here 1.55
0 · Reply
wolfcyd3
wolfcyd3 Feb. 11 at 4:42 PM
$RNTX added 20k shares today
1 · Reply
BatteryBaron
BatteryBaron Feb. 9 at 2:58 PM
$RNTX Renal therapy biotech; faces established standard of care.
0 · Reply
Dlslfl
Dlslfl Jan. 30 at 10:52 PM
$RNTX bullish? :) u guy's all stupid Me too
0 · Reply
Dlslfl
Dlslfl Jan. 27 at 4:46 AM
$RNTX have news?
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 1:33 AM
$RNTX
1 · Reply
hitmongreen
hitmongreen Jan. 23 at 8:51 PM
$RNTX 🤔
0 · Reply
MomentumWins
MomentumWins Jan. 20 at 1:54 PM
$SPY $QQQ looks like this will be green $RNTX
0 · Reply
DARKP00L
DARKP00L Jan. 20 at 1:13 PM
$RNTX 08:08 on Jan. 20 2026 Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03 #tradeideas
0 · Reply
jamal1749
jamal1749 Jan. 20 at 1:09 PM
$RNTX trash
0 · Reply
jamal1749
jamal1749 Jan. 20 at 1:03 PM
$RNTX how did it go down on this news.
0 · Reply
premarketmaker
premarketmaker Jan. 20 at 1:03 PM
$RNTX first resistance on ask - $3.05
0 · Reply
premarketmaker
premarketmaker Jan. 20 at 1:02 PM
$RNTX very low amount of shares on the ask
0 · Reply
premarketmaker
premarketmaker Jan. 20 at 1:01 PM
$RNTX orphan drug -pulmonary fibrosis lower float
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 19 at 10:14 AM
$RNTX Current Stock Price: $1.22
0 · Reply
MomentumWins
MomentumWins Jan. 2 at 3:00 PM
$RNTX bull market is back. we should see 2’s again
0 · Reply